Advertisement

Current Diabetes Reports

, 14:535 | Cite as

The Epidemiology of Diabetes and Cancer

  • Bendix Carstensen
  • Marit Eika Jørgensen
  • Søren Friis
Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Diabetes and Other Diseases—Emerging Associations

Abstract

The literature on cancer occurrence in persons with diabetes has almost invariably been concerned with relative measures. In this paper, we briefly review this, but the aim is to quantify the absolute occurrence of diabetes and cancer in the population in order to give a fuller picture, which also includes the competing mortality risk. Overall, we find that some 35 % of the population will have a diagnosis of diabetes in their lifetime, 44 % a diagnosis of cancer, and about 15 % will have both diagnoses. The impact of differing mortality between persons with and without diabetes is illustrated by the fact that a person without diabetes at age 50 has a smaller lifetime risk of cancer than a person aged 50 with diabetes. Thus, the differences in cancer occurrence between persons with and without diabetes are of quantitatively smaller importance than the differences in mortality.

Keywords

Diabetes and cancer Epidemiology Demography Lifetime risk of diabetes and cancer Absolute risk of diabetes 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Bendix Carstensen and Marit Eika Jørgensen are employees of Steno Diabetes Center, a research Hospital owned by Novo Nordisk and operating as part of the Danish National Health Service. Bendix Carstensen and Marit Eika Jørgensen own shares in Novo Nordisk.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Wideroff L, Gridley G, Mellemkjær L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.PubMedCrossRefGoogle Scholar
  5. 5.
    HM Colhoun the SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65.CrossRefGoogle Scholar
  6. 6.
    Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.PubMedCrossRefGoogle Scholar
  7. 7.
    Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.••
    Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run. Google Scholar
  9. 9.•
    Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRefGoogle Scholar
  10. 10.•
    Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRefGoogle Scholar
  11. 11.
    Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H. The Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.PubMedCrossRefGoogle Scholar
  14. 14.
    Kajüter H, Geier AS, Wellmann I, Krieg V, Fricke R, Heidinger O, et al. Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2. Bundesgesundheitsblatt. 2014;57:52–9.CrossRefGoogle Scholar
  15. 15.
    Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Carstensen B, Christensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 suppl):58–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–219.PubMedCrossRefGoogle Scholar
  18. 18.
    Gjerstorff ML. The Danish cancer registry. Scand J Public Health. 2011;39(7 Suppl):42–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Human Mortality Database. University of California, Berkeley (USA), Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org or www.humanmortality.de (data downloaded on 20 April 2014).
  20. 20.
    Carstensen B. Age-period-cohort models for the Lexis diagram (author’s reply). Stat Med. 2007;27:1561–4.CrossRefGoogle Scholar
  21. 21.•
    Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Bendix Carstensen
    • 1
    • 2
  • Marit Eika Jørgensen
    • 1
  • Søren Friis
    • 3
    • 4
  1. 1.Clinical EpidemiologySteno Diabetes CenterGentofteDenmark
  2. 2.Department of BiostatisticsUniversity of CopenhagenKøbenhavnDenmark
  3. 3.Research CenterDanish Cancer SocietyKøbenhavnDenmark
  4. 4.Department of Public HealthUniversity of CopenhagenKøbenhavnDenmark

Personalised recommendations